IMPORTANT INFORMATION ABOUT MAVIRET®
MAVIRET® is a prescription medicine containing a combination tablet of 100 mg of glecaprevir and 40 mg of pibrentasvir. It is used to treat chronic (long-lasting) hepatitis C virus (HCV) in adult patients.
MAVIRET has risks and benefits.
Before using MAVIRET® tell your doctor if you have liver problems other than hepatitis C infection, HIV infection, hepatitis B infection, a liver or kidney transplant; if you are pregnant, trying to become pregnant or are breastfeeding; or if you are taking any medicines or supplements.
If you have any questions about using MAVIRET, including its risks and benefits, how much to use, how and when to use it, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available from www.medsafe.govt.nz or free phone 0800 900 030.
Ask your doctor if MAVIRET is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.
Normal doctor's charges apply. MAVIRET is a fully funded prescription medicine with an alternative arrangement on how it is available to you. Your prescriber will explain this to you. AbbVie Limited, 6th floor, 156-158 Victoria Street, Wellington 6011, New Zealand.
TAPS PP2579. NZ-MAVI-180053. Date of revision February 2019.
